Gilead Sciences shares set to trade higher after remdesivir to become first European Covid-19 therapy
Shares in the US-based biotech company are likely to trend higher after its Covid-19 therapy remdesivir gets the go-ahead in Europe.
Gilead Sciences shares are likely to trend higher in the near-term after its antiviral drug remdesivir is set to become Europe’s first Covid-19 therapy.
Gilead Sciences is trading at $74.70 per share at the time of publication.
Healthcare regulators from the European Medicines Agency (EMA) approved the antiviral drug on Thursday by its Human Medicines Committee (CHMP), who recommended that the drug be used to treat adults and adolescents from 12 years old who are suffering severe coronavirus symptoms.
The EMA endorsement of Gilead Sciences antiviral drug allows remdesivir to be prescribed by European doctors, subject to the EU Commission giving the go ahead, which is expected to happen in a matter of days.
Can Gilead Sciences meet demand for remdesivir?
As of yet, the price point for remdesivir in Europe is unknown. However, in the US, where it is already being used as a treatment for the coronavirus pandemic it costs $5080 per round.
Appetite for the antiviral drug remains high around the world, but investors have expressed concern about whether Gilead Sciences will be able to manufacture enough of it to adequately meet demand.
As it stands, the US-based biotech company said that it will be able to provide more than two million courses of its antiviral drug, which will be branded under the name Veklury, by the end of 2020 – representing a two-fold increase on its previous supply target.
Analysts optimistic about Gilead Sciences share price
Since remdesivir’s drug trials on humans showed promise of treating Covid-19 patients the company’s stock has outperformed the broader market, with its share price up14% year-to-date compared with the S&P 500 which, despite a valiant recovery of late, is 6% down over the same period.
The 23 analysts offering 12-month price forecasts for Gilead Sciences have a median target of $81 per share, with a high estimate of $97 and a low estimate of $58.
The median estimate represents a 8.4% increase from its current level. Meanwhile, the high estimate implies a potential upside of up 29.8% and the low estimate suggests the stock could fall by as much as 22.3%.
How to trade stocks with IG
- Create an IG trading account or log in to your existing account
- Enter ‘Gilead Sciences’ in the search bar and select it
- Choose your position size
- Click on ‘buy’ or ‘sell’ in the deal ticket
- Confirm the trade
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.